Drugs / PL001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05326243 | May 2022 → Dec 2026 expected | large B-cell lymphoma, primary mediastinal large B-cell lymphoma | Pell Bio-Med Technology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PL001 | “CD19 CAR-T(also known as PL001)” NCT05326243 ↗ |
| Modality | Cell therapy | “CD19 CAR-T therapy” NCT05326243 ↗ |
| Target | CD19 | “CD19-targeted chimeric antigen receptor T-cell (CD19 CAR-T)” NCT05326243 ↗ |